NCT07142369

Brief Summary

The purpose of this study is to determine what effects the withdrawal of excess knee joint fluid or the injection of a factor from the blood has on swelling after a sudden anterior cruciate ligament (ACL) rupture of the knee.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
99

participants targeted

Target at P50-P75 for not_applicable

Timeline
32mo left

Started May 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress1%
May 2026Dec 2028

First Submitted

Initial submission to the registry

August 19, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 26, 2025

Completed
8 months until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2028

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Last Updated

February 12, 2026

Status Verified

February 1, 2026

Enrollment Period

2.4 years

First QC Date

August 19, 2025

Last Update Submit

February 11, 2026

Conditions

Keywords

osteoarthritis

Outcome Measures

Primary Outcomes (1)

  • Concentration of Collagen Type II Cytokine

    Breakdown cytokine found in damaged cartilage

    Enrollment up to surgery

Study Arms (3)

Two Synovial Fluid Withdrawals

ACTIVE COMPARATOR

Subjects randomized to Arm 1 will have 2 synovial fluid withdrawals; one at the preoperative clinic visit and one at the time of surgery

Procedure: Synovial Fluid withdrawal at the preoperative clinic visitProcedure: Synovial fluid withdrawal at the time of surgery

Platelet-Rich Plasma (PRP) and Two Synovial Fluid Withdrawals

EXPERIMENTAL

Subjects randomized to ARM 2 will have 2 synovial fluid withdrawals one at the preoperative visit and one at the time of surgery. Platelet-Rich Plasma (PRP) preparation and injection will happen at the preoperative clinic visit.

Procedure: Synovial Fluid withdrawal at the preoperative clinic visitProcedure: Platelet-Rich Plasma (PRP) preparation and injectionProcedure: Synovial fluid withdrawal at the time of surgery

3mL Synovial Fluid Withdrawal and Synovial Fluid Withdrawal at the Time of Surgery

OTHER

Subjects randomized to Arm 3 will have 3mL withdrawal of synovial fluid at the preoperative visit and 1 synovial fluid withdrawal at the time of surgery

Procedure: Synovial fluid withdrawal at the time of surgeryProcedure: 3mL synovial fluid withdrawn at the preoperative visit

Interventions

Synovial Fluid withdrawal at the preoperative clinic visit

Also known as: arthrocentesis
Platelet-Rich Plasma (PRP) and Two Synovial Fluid WithdrawalsTwo Synovial Fluid Withdrawals

Platelet-Rich Plasma (PRP) preparation and injection

Also known as: platelet rich plasma
Platelet-Rich Plasma (PRP) and Two Synovial Fluid Withdrawals

Synovial fluid withdrawal at the time of surgery

3mL Synovial Fluid Withdrawal and Synovial Fluid Withdrawal at the Time of SurgeryPlatelet-Rich Plasma (PRP) and Two Synovial Fluid WithdrawalsTwo Synovial Fluid Withdrawals

3mL synovial fluid withdrawn at the preoperative visit

3mL Synovial Fluid Withdrawal and Synovial Fluid Withdrawal at the Time of Surgery

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18 - 50
  • English-speaking
  • Clinical evidence of ACL rupture with swelling
  • Participant must be undergoing ACL reconstruction surgery

You may not qualify if:

  • Age \<18 or \>50
  • Presentation \>3 weeks after initial injury
  • Previous traumatic ipsilateral (same side) knee injury consistent with chronic ACL tear or prior ACL surgery
  • \> Kellgren-Lawrence grade 2 changes on preoperative x-ray
  • History of hemophilia or inflammatory arthropathy (e.g., rheumatoid arthritis)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rush University Medical Center

Chicago, Illinois, 60612, United States

Location

MeSH Terms

Conditions

RuptureOsteoarthritis

Interventions

ArthrocentesisInjections

Condition Hierarchy (Ancestors)

Wounds and InjuriesArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

ParacentesisSpecimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesTherapeuticsSurgical Procedures, OperativeInvestigative TechniquesDrug Administration RoutesDrug Therapy

Study Officials

  • Adam Yanke, MD, PhD

    Associate Professor and Surgeon

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jorge Chahla, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Randomized control trial 1:1:1 study assignment (33 subjects Arm 1 two arthrocentesis withdrawals; 33 subjects Arm 2 two arthrocentesis withdrawals with PRP injection; 33 subjects Arm 3 a very small arthocentesis withdrawal and one standard arthrocentesis withdrawal and no PRP injection)
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 19, 2025

First Posted

August 26, 2025

Study Start

May 1, 2026

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

December 1, 2028

Last Updated

February 12, 2026

Record last verified: 2026-02

Locations